detail and have been the center of much attention in recent years. These two pathways for apoptosis are commonly referred to as the Intrinsic and Extrinsic pathways (Figure 1 ) 3 .
The intrinsic pathway centers on mitochondria as initiators of cell death. Multiple signals converge on mitochondria, including DNA damage, hypoxia, and oxidative stress, causing these organelles to release cytochrome c (cyt c) and other apoptogenic proteins into cytosol. In the cytosol, cyt c binds caspase-activating protein Apaf1, triggering its oligomerization into a hepatmeric complex that binds pro-caspase-9, forming a multi-protein structure known as the "apoptosome" 4 . Physical binding of Apaf1 to pro-caspase-9 is mediated by their Caspase Recruitment Domains (CARDs), through homotypic CARD-CARD binding. Activation of apoptosome-associated cell death protease caspase-9 then initiates a proteolytic cascade, where activated caspase-9 cleaves and activates downstream effector proteases, such as pro-caspase-3.
In contrast, the extrinsic apoptotic pathway relies on TNF (Tumor Necrosis Factor)-family death receptors for triggering apoptosis. A subgroup of the TNF-family receptors contain a cytosolic Death Domain, that enables their intracellular interaction with downstream adapter proteins, linking these receptors to specific caspases. Upon ligand binding, TNF-family receptors containing cytosolic Death Domains cluster in membranes, recruiting caspase-binding adaptor proteins, including the bipartite adapter FADD that contains both a Death Domain (DD) and a Death Effector Domain (DED) 5 . The DED of FADD binds DED-containing pro-caspases (e.g. caspases-8 and -10), forming a "death inducing signaling complex" (DICS) and resulting in caspase activation by an "induced proximity" mechanism 1 .
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From A delicate balance between pro-apoptotic and anti-apoptotic regulators of apoptosis pathways is at play on a continual basis, ensuring the survival of long-lived cells and the proper turnover of short-lived cells in a variety of tissues, including the bone marrow, thymus, and peripheral lymphoid tissues. However, imbalances in this delicate dance of proand anti-apoptotic proteins occur in disease scenarios, including cancer where the scales tip in favor of anti-apoptotic proteins, endowing cells with a selective survival advantage that promotes neoplasia and malignancy.
Drug discovery strategies directed at core components of the apoptosis machinery
The apoptosis-blocking proteins that thwart signaling through specific apoptosis pathways provide targets for possible drug discovery, as do agents that stimulate proapoptotic proteins within these cell death pathways. Theoretically, all drug targets can be addressed in multiple ways, modulating the activity of the target at the levels of the DNA (gene expression), mRNA, or protein. A summary of some of the more promising strategies for altering the activity of apoptosis genes and proteins for cancer therapy is provided below, according to the apoptosis pathways they modulate.
Intrinsic pathway
Bcl-2-family proteins are the most prominent of the intrinsic pathway targets for cancer drug discovery. Though the human genome contains 25 members of this gene family, only six are anti-apoptotic and thus represent logical targets for therapy: Bcl-2, Bcl-X L , MclFor personal use only. on October 28, 2017. by guest www.bloodjournal.org From 1, Bcl-W, Bfl-1, and Bcl-B. Over-expression of several of these anti-apoptotic Bcl-2-family proteins has been documented in various hematopoietic malignancies, though data are most extensive for the founding member of the family Bcl-2 (reviewed in 6, 7 ; (e) A-779024, a synthetic small-molecule inhibitor produced by NMR-guided, structurebased drug design (Abbott), and others 32 (Table 1) For example, an orphan member of the retinoid/steroid family of nuclear receptors, TR3 (Nur77) translocates from nucleus to cytosol in response to certain cell death stimuli 42 . In the cytosol, TR3 binds a regulatory domain within the Bcl-2 protein, thus accounting for accumulation of TR3 on mitochondria. TR3 induces a profound conformational change of Bcl-2, causing BH3 domain exposure and converting Bcl-2 from a protector to a killer 43 .
The BH3 domain of Bcl-2 binds pro-apoptotic Bcl-2-family members Bax and Bak, as well as anti-apoptotic Bcl-2-family proteins, probably activating the pro-apoptotic while inactivating the anti-apoptotic ( Figure 3 ).
Recently, a class of compounds representing analogs of the retinoid AHPN has been identified that induce TR3 expression and translocation into the cytosol. The prototype compound, 3Cl-AHPC, lacks activity against retinoid receptors, though having evolved from attempts to synthesize highly selective retinoid ligands 44 . 3Cl-AHPC has demonstrated activity against cultured leukemia cells and in preclinical animal models of AML 45, 46 , retaining activity even against retinoid refractory leukemia cell lines. 3Cl-AHPC appears to induce phosphorylation of TR3, possibly via a Jun N-terminal kinase (JNK) pathway, correlating with its exodus from the nucleus 47 . This compound may therefore provide a mechanism to invoke the TR3 pathway, converting Bcl-2 from a protector to a killer, and thus making Bcl-2 a liability rather than an advantage for malignant cells.
Opposing this TR3-mediated pathway for apoptosis is Akt/PKB, which appears to nullify pro-apoptotic actions of TR3 by phosphorylation at Serine 530 48, 49 . with alkylating agents, which may not provide a synergistic combination. New targets for drug discovery are also emerging from studies of these endogenous pathways, such as compounds that enhance wild type P53 by blocking interactions with Mdm2 (Table 3) 57 .
Extrinsic pathway
The extrinsic pathway is activated by TNF-family ligands that engage TNF-family death-receptors, resulting in activation of caspases and apoptosis. Interest has emerged in therapeutics that kill cancer cells via the extrinsic pathway, particularly since chemorefractory cells often have defects in their intrinsic pathway, given the predominant reliance of cytotoxic drugs and x-irradiation on the mitochondrial cell death pathway 58 . In this regard, the TNF cytokine family consists of 18 members in humans, with 29 counter 
suggested opportunities for engaging the extrinsic pathway at other levels, improving sensitivity of malignant cells to biologicals that activate the extrinsic pathway.
TNF-family ligands and receptor-targeting antibodies. Over 3 decades ago, TNF was reported to selectively kill tumor but not normal cells, raising hopes that this cytokine might be exploited for cancer treatment 60 . Unfortunately, the pro-inflammatory actions of TNF precluded its systemic administration, and squelched efforts to apply it clinically. Then, we knew little about how TNF transduces signals into cells making it difficult to propose alternative strategies. Today, we have an in-depth knowledge of the pathways that TNF and related cytokines activate, and from this knowledge has come several potential targets for drug discovery. We also understand far better how TNF-family cytokines regulate pathways that control apoptosis, and we can begin to envision ways of exploiting that knowledge for sensitizing tumors to these cytokines that immune cells employ for battling cancer. The absence of proinflammatory effects of FasL and TRAIL has raised hopes that they might be successfully applied for cancer therapy, where TNF failed due to toxicity.
While agonistic antibodies that trigger the Fas (CD95) are unfortunately highly toxic to liver 66 , TRAIL and agonistic antibodies that bind TRAIL-receptors appear to be well tolerated in vivo. Indeed, Phase I clinical trials have recently been completed using an agonistic monoclonal antibody ETR1 (Human Genome Sciences), directed against TRAIL-Receptor-1 (TRAIL-R1) [DR4], revealing little toxicity 67 . In mouse xenograft models using selected tumor human cells lines, TRAIL and agonistic antibodies directed against TRAIL-receptors exhibit potent antitumor activity and often synergize with chemotherapy 68 , raising hopes of using these biological agents as a novel approach to cancer treatment and thereby mimicking some of the effector mechanisms employed by the immune system in its defense against transformed cells. .
Intracellular modifiers of extrinsic pathway -drug targets. Among the prominent modulators of sensitivity to TNF-family death receptors are NF B-family transcription
Pharmacological inhibition of proteasome activity suppresses I B degradation, but also has effects on stability of many cellular proteins, and thus the anti-tumor activity of proteasome inhibitors may only partly be related to NF B activity.
FLIP. Many leukemias and lymphomas exhibit intrinsic resistance to TNF, TRAIL, and
FasL, despite expressing the necessary cell-surface receptors 83 . Multiple antagonists of the extrinsic pathway have been identified, including several DED-containing proteins that compete for binding to the adapter proteins or pro-caspases that participate in TNF-family death receptor signaling 84 . Among these, FLIP has received the most attention for its role in producing Fas-and TRAIL-resistant states in tumor cells 85, 86 92 .
Convergence pathway
The intrinisic and extrinsic pathways for apoptosis converge on downstream effector Table 2 ). The phenylureas exhibit broad-spectrum apoptosis-inducing activity against cultured tumor cell lines and primary leukemias, and suppress growth of tumor xenografts in mice without apparent toxicity to normal tissues 103 . Importantly, these compounds induce apoptosis through a Bcl-2/Bcl-X L -independent mechanism, suggesting they may prove useful for chemorefractory cancers and leukemias. Reported antagonists targeting the SMAC binding site include natural product, embelin 109 , various peptidiomimetics and nonpeptidic small molecules [110] [111] [112] (Table 2) .
Besides SMAC and OMI, additional endogenous antagonists of IAPs have been described: ARTS, XAF1, and NRAGE 113-115 ( Figure 6 ). Structural details of how these proteins interact with IAP targets are unknown, but could provide additional strategies for generation of small-molecule antagonists that work through non-SMAC mechanisms. Given that the reported phenylurea-base antagonists of XIAP target a non-SMAC site on XIAP 103 , it will be interesting to determine whether those compounds mimic ARTS, NRAGE or XAF1 in terms of their docking site on XIAP.
For Survivin is particularly attractive, because the mechanism by which this protein suppresses caspases differs from most other IAPs 117 , and a clear path forward for compound discovery remains uncertain based on protein structure data 33 . In addition, a phosphorothioate-based antisense ODN targeting XIAP (AEG35156/GEM640 ) has been designated for human clinical trials (Agera Pharmaceuticals). It remains to be determined whether a highly selective (antisense) versus broad-spectrum (small-molecule) approach to attacking IAPs will yield the optimal therapeutic index.
Conclusions
Emerging knowledge about molecular mechanism of apoptosis dyregulation in cancer and leukemia has revealed a plethora of potential drug discovery targets. Structural analysis of apoptosis proteins and studies of their biochemical mechanisms have suggested strategies for For those with the stamina, the rewards are likely to be great, creating a new era in cancer therapy where the intrinsic or acquired resistance of malignant cells to apoptosis can be pharmacologically reversed, reinstating natural pathways for cell suicide. Table 2 For personal use only. For personal use only.
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